CureVac Stock: BioNTech's Billion-Dollar Takeover Bid

The biotech landscape was shaken Thursday as BioNTech announced a takeover offer for Tübingen-based CureVac, valuing the company at approximately $1.25 billion (€1.08 billion). Under the proposed deal, CureVac shareholders would receive BioNTech American Depositary Shares worth about $5.46 per CureVac share. The news triggered an explosive market response, with CureVac's stock surging nearly 40% to $5.68 on Nasdaq, reaching its highest level since late 2023 and even exceeding the offer price. The transaction, expected to close by the end of 2025 pending regulatory approval, has already secured support from key stakeholders holding over 36% of CureVac shares, including SAP co-founder Dietmar Hopp's investment firm.

Strategic Implications Beyond Financials

BioNTech's acquisition move appears strategically motivated beyond mere expansion, potentially resolving ongoing patent disputes between the former competitors that were headed for court within weeks. For BioNTech, the deal represents a significant step in strengthening its oncology division, marking its second billion-dollar investment in cancer research within a short timeframe. The Mainzer company plans to leverage CureVac's expertise and technology platforms while maintaining the Tübingen research site. To complete the transaction, BioNTech must reach an 80% acceptance threshold from outstanding CureVac shares, with plans to offer equivalent terms to remaining shareholders through restructuring if necessary.

Ad

Fresh CureVac information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld